53 In both Phase 1a and 1b trials, it has been established that orforglipron does not have food or water administration restrictions and may provide a safe and effective oral treatment option for patients with T2D and other indications
When the upper arm makes sense The upper arm offers a middle ground in absorption characteristics, falling between the abdomen and thigh in most pharmacokinetic comparisons
Its also important to note the distinction between lipedema and obesity, as individuals with lipedema may meet BMI thresholds but require different treatment approaches
Tech Stack & Integrations About working with us Why it matters Fridays Health exists to address a critical gap in the GLP-1 healthtech market: accessible, evidence-based treatment for obesity as a chronic metabolic condition, what digital health founders should focus in the GLP-1 market
For instance, according to the International Diabetes Federation Diabetes Atlas (2021 edition), China and India were estimated to have 140.9 million and 74.2 million adults with diabetes in 2021, and these numbers are projected to increase to 174.4 million and 124.9 million, respectively, by 2045
